STOCK TITAN

Edwards Lifesciences exec sells 31,800 shares

(Neutral)
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Edwards Lifesciences Corp (EW) executive Daveen Chopra, CVP, TMTT, Surgical & IHFM, exercised 31,800 Employee Stock Options for Common Stock at an exercise price of $72.68 per share and simultaneously sold 31,800 shares of Common Stock on 2026-08-26 in open-market transactions. The sales comprised 1,154 shares at a weighted average price of $91.7614 (individual trades ranged from $91.660 to $91.975) and 30,646 shares at a weighted average price of $90.9922 (trades ranged from $90.645 to $91.640). The option, originally exercisable since 2021-05-07 and expiring on 2027-05-06, now shows 0 options remaining in this grant.

Positive

  • None.

Negative

  • None.
Insider Chopra Daveen
Role CVP, TMTT, Surgical & IHFM
Sold 31,800 shs ($2.89M)
Approx. gross sale proceeds $2.89M
Approx. exercise cost $2.31M
Approx. pre-tax spread $583K
Type Security Shares Price Value
Exercise Employee Stock Option (Right to Acquire) 31,800 $0.00 $0.00
Exercise Common Stock 31,800 $72.68 $2.31M
Sale Common Stock F1 1,154 $91.7614 $106K
Sale Common Stock F2 30,646 $90.9922 $2.79M
Holdings After Transaction: Employee Stock Option (Right to Acquire) — 0 contracts (Direct); Common Stock — 44,324 shares (Direct)
Footnotes (2)
  1. F1. This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
  2. F2. This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Options exercised 31,800 shares Employee Stock Option (Right to Acquire) exercised into Common Stock on 2026-08-26
Option exercise price $72.68 per share Exercise price of Employee Stock Option originally exercisable 2021-05-07, expiring 2027-05-06
Shares sold (block 1) 1,154 shares Common Stock sale on 2026-08-26 at weighted average price $91.7614
Weighted average sale price (block 1) $91.7614 per share Multiple trades between $91.660 and $91.975 for 1,154 shares
Shares sold (block 2) 30,646 shares Common Stock sale on 2026-08-26 at weighted average price $90.9922
Weighted average sale price (block 2) $90.9922 per share Multiple trades between $90.645 and $91.640 for 30,646 shares
Options remaining from this grant 0 options Total shares following transaction for the derivative security
Net shares sold 31,800 shares Transaction summary netBuySellShares across reported buy/sell transactions
Employee Stock Option (Right to Acquire) financial
"security_title: "Employee Stock Option (Right to Acquire)""
beneficial ownership financial
"reflects changes in beneficial ownership only; it does not identify other"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open market or private transaction financial
"transaction_code_description": "Sale in open market or private transaction""

FAQ

What insider transactions did EW executive Daveen Chopra report on this Form 4?

Daveen Chopra reported exercising 31,800 stock options at $72.68 per share into Common Stock and selling a total of 31,800 shares of Edwards Lifesciences Corp Common Stock in open-market transactions on 2026-08-26.

At what prices were Daveen Chopra’s EW stock options exercised and shares sold?

The options were exercised at an exercise price of $72.68 per share. Shares were sold in two blocks: 1,154 shares at a weighted average of $91.7614 and 30,646 shares at a weighted average of $90.9922 per share, each executed in multiple trades within stated price ranges.

How many Edwards Lifesciences (EW) options did Daveen Chopra have left from this grant after the transaction?

For the reported Employee Stock Option grant, the filing shows 31,800 options exercised and 0 options remaining following the transaction, as reflected in the total shares following transaction field for that derivative security.

What were the trade price ranges for Daveen Chopra’s EW share sales on 2026-08-26?

For 1,154 shares, trades occurred between $91.660 and $91.975 with a weighted average of $91.7614. For 30,646 shares, trades occurred between $90.645 and $91.640 with a weighted average of $90.9922 per share.

Were Daveen Chopra’s EW transactions made under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is false, and the footnotes do not state that the transactions were made pursuant to a Rule 10b5-1 trading plan.

What role does Daveen Chopra hold at Edwards Lifesciences (EW) according to this Form 4?

According to the Form 4, Daveen Chopra is an officer of Edwards Lifesciences Corp with the title CVP, TMTT, Surgical & IHFM. The reported transactions reflect changes in his beneficial ownership of the company’s securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Chopra Daveen

(Last)(First)(Middle)
ONE EDWARDS WAY

(Street)
IRVINE CALIFORNIA 92614

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Edwards Lifesciences Corp [ EW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CVP, TMTT, Surgical & IHFM
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/26/2026M31,800A$72.6876,124D
Common Stock08/26/2026S1,154D$91.7614(1)74,970D
Common Stock08/26/2026S30,646D$90.9922(2)44,324D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Acquire)$72.6808/26/2026M31,80005/07/202105/06/2027Common Stock31,800$0.00000.0000D
Explanation of Responses:
1. This transaction was executed in multiple trades at prices ranging from $91.660 to $91.975. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
2. This transaction was executed in multiple trades at prices ranging from $90.645 to $91.640. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Remarks:
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.
Linda J. Park, Attorney-in-Fact08/26/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)